X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ORCHID PHARMA LTD - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ORCHID PHARMA LTD WYETH LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 27.7 -0.5 - View Chart
P/BV x 5.3 0.4 1,445.0% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ORCHID PHARMA LTD
Sep-13
WYETH LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,044194 538.4%   
Low Rs81835 2,337.1%   
Sales per share (Unadj.) Rs298.6276.5 108.0%  
Earnings per share (Unadj.) Rs57.2-79.2 -72.3%  
Cash flow per share (Unadj.) Rs58.4-43.5 -134.4%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.553.9 462.5%  
Shares outstanding (eoy) m22.7270.45 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.10.4 753.1%   
Avg P/E ratio x16.3-1.4 -1,125.4%  
P/CF ratio (eoy) x15.9-2.6 -605.0%  
Price / Book Value ratio x3.72.1 175.8%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1578,067 262.3%   
No. of employees `0000.52.8 17.6%   
Total wages/salary Rs m4002,527 15.8%   
Avg. sales/employee Rs Th13,787.46,956.1 198.2%   
Avg. wages/employee Rs Th813.0902.5 90.1%   
Avg. net profit/employee Rs Th2,643.3-1,993.0 -132.6%   
INCOME DATA
Net Sales Rs m6,78319,477 34.8%  
Other income Rs m353407 86.6%   
Total revenues Rs m7,13619,884 35.9%   
Gross profit Rs m1,6171,103 146.7%  
Depreciation Rs m272,519 1.1%   
Interest Rs m65,227 0.1%   
Profit before tax Rs m1,938-6,236 -31.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5511 -1.0%   
Tax Rs m632-125 -505.0%   
Profit after tax Rs m1,301-5,580 -23.3%  
Gross profit margin %23.85.7 421.2%  
Effective tax rate %32.62.0 1,625.0%   
Net profit margin %19.2-28.7 -66.9%  
BALANCE SHEET DATA
Current assets Rs m6,98411,014 63.4%   
Current liabilities Rs m2,05632,060 6.4%   
Net working cap to sales %72.6-108.1 -67.2%  
Current ratio x3.40.3 988.8%  
Inventory Days Days9995 104.6%  
Debtors Days Days2434 71.3%  
Net fixed assets Rs m24429,440 0.8%   
Share capital Rs m227705 32.2%   
"Free" reserves Rs m5,4412,043 266.4%   
Net worth Rs m5,6683,800 149.2%   
Long term debt Rs m259,018 0.3%   
Total assets Rs m7,90146,510 17.0%  
Interest coverage x353.3-0.2 -182,957.3%   
Debt to equity ratio x02.4 0.2%  
Sales to assets ratio x0.90.4 205.0%   
Return on assets %16.5-0.8 -2,174.8%  
Return on equity %22.9-146.9 -15.6%  
Return on capital %34.0-3.7 -911.6%  
Exports to sales %0.237.9 0.6%   
Imports to sales %36.322.6 160.7%   
Exports (fob) Rs m157,378 0.2%   
Imports (cif) Rs m2,4654,406 56.0%   
Fx inflow Rs m157,513 0.2%   
Fx outflow Rs m2,6775,649 47.4%   
Net fx Rs m-2,6621,865 -142.8%   
CASH FLOW
From Operations Rs m9231,682 54.9%  
From Investments Rs m317-9,860 -3.2%  
From Financial Activity Rs m-4816,644 -7.2%  
Net Cashflow Rs m759-1,535 -49.5%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 4.6 245.7%  
FIIs % 7.2 3.3 218.2%  
ADR/GDR % 0.0 4.6 -  
Free float % 30.4 55.3 55.0%  
Shareholders   21,978 84,811 25.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare WYETH LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - PIRAMAL ENTERPRISES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS